C4 Therapeutics (NASDAQ:CCCC) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.
Analyst Recommendations
This is a breakdown of current recommendations for C4 Therapeutics and NanoString Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
C4 Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
NanoString Technologies | 0 | 1 | 4 | 0 | 2.80 |
C4 Therapeutics currently has a consensus price target of $44.50, suggesting a potential upside of 36.71%. NanoString Technologies has a consensus price target of $68.60, suggesting a potential downside of 6.04%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe C4 Therapeutics is more favorable than NanoString Technologies.
Earnings and Valuation
This table compares C4 Therapeutics and NanoString Technologies' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
C4 Therapeutics | N/A | N/A | N/A | N/A | N/A |
NanoString Technologies | $125.57 million | 25.92 | $-40,700,000.00 | ($1.93) | -37.83 |
C4 Therapeutics has higher earnings, but lower revenue than NanoString Technologies.
Profitability
This table compares C4 Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
C4 Therapeutics | N/A | N/A | N/A |
NanoString Technologies | -53.47% | -68.96% | -24.15% |
Insider & Institutional Ownership
98.3% of NanoString Technologies shares are held by institutional investors. 4.2% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
C4 Therapeutics beats NanoString Technologies on 5 of the 9 factors compared between the two stocks.